Rallybio

Rallybio

Biotechnology
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

$90.4M

Market Cap • 10/9/2026

2020

(6 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1

P/S

139,9

P/EBITDA

—

P/OCF

3,4

P/FCF

3,4

P/E

2,1

BVPS

17,8

EPS

7,9

Market Cap

Market Cap

90,4M

EV

-2,5M

EV/Revenue

-3,8

EV/EBITDA

0,1

EV/EBIT

0,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

-266,6M

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

7051,2%

D&A/EBITDA

0%

R&D/Revenue

1768,9%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

10,7%

% PPE

0%

% Goodwill

0%

ROE

64,9%

ROIC

—

Growth

CAGR Op. Income 5Y

-7,1%

Leverage

N.D./EBITDA

3,4

Debt/Equity

0%

Current Ratio

27,3

Quick Ratio

26

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium